June 24th 2024
A recent review found the antifibrinolytic drug performed well in several clinical studies, none of which reported severe adverse events.
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Neuromodulators Combat Key Rosacea Challenges
April 22nd 2021In treatments addressing muscular contraction, botulinum toxin inhibits nerves that innervate blood vessels from releasing acetylcholine, which triggers vasodilation. Its impact on the innate immune system suggests that botulinum toxin may also help reduce recalcitrant rosacea-related papules and pustules.
AI-powered diagnostic tool accurately identifies rosacea
November 10th 2020A new artificial intelligence-powered diagnostic tool, Ros-NET, was able to accurately identify rosacea, making way for further development of the technology to aid in diagnosis of the skin condition, according to a recent study.
Misinformation delays rosacea diagnosis in skin of color patients
October 16th 2020The idea that rosacea is uncommon in darker skinned individuals may be due to under-recognition. Careful clinical examination, a thorough history and biopsy in some cases are needed for accurate diagnosis and differentiating rosacea from diseases that may be more common.
FDA accepts NDA filing for topical papulopustular rosacea treatment
September 14th 2020The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) filing for Sol-Gel’s Epsolay, a 5% microencapsulated benzoyl peroxide cream for the treatment of inflammatory lesions of rosacea or papulopustular rosacea.
Phenotypes inform management options
August 20th 2020Many patients with rosacea have features that overlap more than one subtype of the condition. A recent publication serves as a compliment to the classification guide with the intention of guiding treatment and management options based on individual patient features.
Specialized skincare regimen improves rosacea symptoms
August 14th 2020Effects of a specialized skincare regimen for sensitive and redness-prone skin were investigated in an eight-week, prospective, controlled clinical trial enrolling 60 patients with rosacea. The intervention was associated with improvements in objectively measured erythema, rosacea symptoms, and health-related quality of life.